网络和计算药物重定位分析用于伯基特淋巴瘤中的c-Myc抑制
Yongmin Lee1, Seungyoon Nam2,3
1Department of Health Sciences and Technology, Gachon Advanced Institute for Health Sciences and Technology (GAIHST), Gachon University, Incheon, Republic of Korea.
Cancer genomics & proteomics
|November 30, 2023
概括
这项研究确定了ERK/MAPK通路作为Burkitt淋巴瘤 (BL) 中c-Myc调节的关键标. 伏利诺斯塔特有效调节这种途径,为BL提供了潜在的新治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物基因组学 药物基因组学
背景情况:
- 伯基特淋巴瘤 (BL) 的治疗率很低,特别是在低收入国家和老年人中.
- c-Myc失调是BL的标志,但其下游途径仍未得到充分研究.
- 确定c-Myc调节的途径对于开发新型BL疗法至关重要.
研究的目的:
- 在伯基特淋巴瘤中识别由c-Myc调节的信号通路.
- 发现针对c-Myc下游信号的潜在治疗剂.
主要方法:
- 来自具有c-Myc抑制的BL细胞系的转录组数据的网络和基因组分析.
- 计算药物重新定位用于识别c-Myc下游途径的调节器.
主要成果:
- 确定ERK/MAPK信号通路是由BL中的c-Myc调节的.
- 沃里诺斯塔特被计算重新设计,并被证明可以调节ERK/MAPK通路.
- 沃里诺斯塔特在BL细胞系中的半最大抑制度 (IC50) <2μM时显示出强烈的疗效.
结论:
- 这项研究首次确定了BL中c-Myc调节的下游信号通路.
- 沃里诺斯塔特成为一个有前途的药物候选者,用于调节BL治疗中的这种途径.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


